Image
Practice Point
Use of potentially cardiotoxic therapies
Avoid or minimise the use of potentially cardiotoxic therapies if established alternatives exist that would not compromise cancer-specific outcomes.
Avoid or minimize the use of potentially cardiotoxic therapies if established alternatives exist that would not compromise cancer-specific outcomes
There is high confidence that the recommendation reflects best practice. This is based on (1) strong evidence for a true net effect (eg,benefits exceed harms); (2) consistent results, with no or minor exceptions; (3) minor or no concerns about study quality; and/or (4) the extent of panelists’ agreement. Other compelling considerations (discussed in the guideline’s literature review and analyses) may also warrant a strong recommendation
How this guidance was developed
This practice point was adopted from the ASCO 2017 (US) guideline on prevention and monitoring of cardiac dysfunction (US) based on a systematic review of the evidence conducted to February 2016. The source recommendation was indicated to be 'consensus-based' rather than 'evidence-based' and the strength of the recommendation was graded ‘strong’ (using ASCO methods) by the source guideline authors.
Related guidance by topic
Use of potentially cardiotoxic therapies
Practice Point
Avoid or minimise the use of potentially cardiotoxic therapies if established alternatives exist that would not compromise cancer-specific outcomes.
Principles in action
Safe and quality care
Image
Multidisciplinary care
This practice point was adopted from the ASCO 2017 (US) guideline on prevention and monitoring of cardiac dysfunction (US) based on a systematic review of the evidence conducted to February 2016. The source recommendation was indicated to be 'consensus-based' rather than 'evidence-based' and the strength of the recommendation was graded ‘strong’ (using ASCO methods) by the source guideline authors.
Related guidance by topic
Image
